We are live on
!
Find out more
SGA
Sector Gamma AS Portfolio holdings
AUM
$423M
1-Year Est. Return
17.56%
This Fund
S&P 500
This Quarter
Est. Return
+2.5%
1 Year Est. Return
+17.56%
3 Year Est. Return
+28.73%
5 Year Est. Return
+52.48%
10 Year Est. Return
+238.19%
AUM
$555M
AUM Growth
-$40.1M
(-6.7%)
Cap. Flow
-$46.8M
Cap. Flow
% of AUM
-8.43%
Top 10 Holdings %
Top 10 Hldgs %
62.94%
Holding
41
New
5
Increased
14
Reduced
11
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cardinal Health
CAH
|
+$15.5M |
| 2 |
SHPG
Shire pic
SHPG
|
+$13.5M |
| 3 |
Ionis Pharmaceuticals
IONS
|
+$10.7M |
| 4 |
Universal Health Services
UHS
|
+$10.3M |
| 5 |
Merck
MRK
|
+$9.44M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$21M |
| 2 |
Gilead Sciences
GILD
|
+$20.2M |
| 3 |
Cigna
CI
|
+$14.9M |
| 4 |
McKesson
MCK
|
+$10.5M |
| 5 |
Perrigo
PRGO
|
+$9.75M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.65% |
| 2 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PTLA
26
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $4.4M | 0.79% |
134,800
+84,800
| +170% | +$3.72M |
|
27
Sarepta Therapeutics
SRPT
$1.78B
| $3.78M | 0.68% |
+51,006
| New | +$3.4M |
|
28
Agios Pharmaceuticals
AGIO
$2.38B
| $3.35M | 0.6% |
+41,000
| New | +$3.17M |
|
|
ONCE
29
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $3.1M | 0.56% |
46,600
-5,900
| -11% | -$341K |
|
|
SGMO
30
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $1.82M | 0.33% |
+96,000
| New | +$2.05M |
|
31
Alnylam Pharmaceuticals
ALNY
$36.4B
| – | – |
-9,400
| Closed | -$1.19M |
|
|
32
Biogen
BIIB
$29.5B
| – | – |
-65,800
| Closed | -$21M |
|
|
33
Cigna
CI
$75.1B
| – | – |
-73,170
| Closed | -$14.9M |
|
34
DaVita
DVA
$15B
| – | – |
-86,680
| Closed | -$6.26M |
|
35
GSK
GSK
$100B
| – | – |
-218,650
| Closed | -$9.69M |
|
|
36
McKesson
MCK
$97.3B
| – | – |
-67,315
| Closed | -$10.5M |
|
37
Viatris
VTRS
$19.8B
| – | – |
-131,361
| Closed | -$5.56M |
|
|
SRCL
38
DELISTED
Stericycle Inc
SRCL
| – | – |
-81,800
| Closed | -$5.56M |
|
|
RDUS
39
DELISTED
Radius Health, Inc.
RDUS
| – | – |
-52,173
| Closed | -$1.66M |
|
|
MNTA
40
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| – | – |
-275,024
| Closed | -$3.84M |
|
|
JUNO
41
DELISTED
Juno Therapeutics, Inc.
JUNO
| – | – |
-43,400
| Closed | -$1.98M |
|
Similar funds
AFWM
MP
DS
RS
DF
OGM
CPIM
MPPLM
Sector Gamma AS's Q1 2018 Portfolio in Review
As of Q1 2018, Sector Gamma AS held 41 positions worth $555M, down 6.7% from $595M the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Sector Gamma AS withdrew a net $46.8M in Q1 2018, closing 11 positions and reducing 11 holdings. Its most notable exit was Biogen, an estimated $21M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Industrials.
Against the trend, Sector Gamma AS opened a new position in Cardinal Health worth $14.2M.
- Sector Gamma AS's largest Q1 2018 buy was Cardinal Health: 226,263 shares worth $14.2M.
- Sector Gamma AS added most to Shire pic in Q1 2018, an estimated $13.5M increase.
- Sector Gamma AS's biggest Q1 2018 reduction was Gilead Sciences, cutting an estimated $20.2M.
- Sector Gamma AS fully exited Biogen in Q1 2018, selling an estimated $21M.
- Sector Gamma AS's ten largest holdings make up 63% of its $555M portfolio in Q1 2018.
- Sector Gamma AS opened 5 new positions and closed 11 in Q1 2018.
- Sector Gamma AS's portfolio value fell 6.7% quarter-over-quarter to $555M.
Based on Sector Gamma AS's 13F filing for Q1 2018, filed 9 May 2018.